GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets

Overview

Journal Front Pharmacol

Date 2018 Jun 7

PMID 29872392

Citations 64

Authors

Paul A Insel

Krishna Sriram

Shu Z Wiley

Andrea Wilderman

Trishna Katakia

Thalia McCann

Hiroshi Yokouchi

Lingzhi Zhang

Ross Corriden

Dongling Liu

Michael E Feigin

Randall P French

Andrew M Lowy

Fiona Murray

Affiliations

Soon will be listed here.

Abstract

G protein-coupled receptors (GPCRs), the largest family of targets for approved drugs, are rarely targeted for cancer treatment, except for certain endocrine and hormone-responsive tumors. Limited knowledge regarding GPCR expression in cancer cells likely has contributed to this lack of use of GPCR-targeted drugs as cancer therapeutics. We thus undertook GPCRomic studies to define the expression of endoGPCRs (which respond to endogenous molecules such as hormones, neurotransmitters and metabolites) in multiple types of cancer cells. Using TaqMan qPCR arrays to quantify the mRNA expression of ∼340 such GPCRs, we found that human chronic lymphocytic leukemia (CLL) cells/stromal cells associated with CLL, breast cancer cell lines, colon cancer cell lines, pancreatic ductal adenocarcinoma (PDAC) cells, cancer associated fibroblasts (CAFs), and PDAC tumors express 50 to >100 GPCRs, including many orphan GPCRs (which lack known physiologic agonists). Limited prior data exist regarding the expression or function of most of the highly expressed GPCRs in these cancer cells and tumors. Independent results from public cancer gene expression databases confirm the expression of such GPCRs. We propose that highly expressed GPCRs in cancer cells (for example, GPRC5A in PDAC and colon cancer cells and GPR68 in PDAC CAFs) may contribute to the malignant phenotype, serve as biomarkers and/or may be novel therapeutic targets for the treatment of cancer.

Citing Articles

Gut colonization of suppresses colitis-associated colon cancer development.

Chen H, Hu P, Chen C, Lin W, Hsu D, Liu F Microbiol Spectr. 2025; 13(2):e0259924.

PMID: 39804065 PMC: 11792494. DOI: 10.1128/spectrum.02599-24.

Proton Sensing GPCR's: The missing link to Warburg's Oncogenic Legacy?.

Cornell J, Rea S, Neitzel L, Williams C, Hong C J Cancer Biol. 2024; 5(2):65-75.

PMID: 39641117 PMC: 11619763. DOI: 10.46439/cancerbiology.5.066.

Mechanistic exploration of bioactive constituents in Gnetum gnemon for GPCR-related cancer treatment through network pharmacology and molecular docking.

Chatatikun M, Pattaranggoon N, Sama-Ae I, Ranteh O, Poolpirom M, Pantanakong O Sci Rep. 2024; 14(1):25738.

PMID: 39468096 PMC: 11519448. DOI: 10.1038/s41598-024-75240-4.

Quantitative proteomics assay reveals G protein-coupled receptor kinase 4-induced HepG2 cell growth inhibition.

Luo Y, Yang J, Wang Y Heliyon. 2024; 10(8):e29514.

PMID: 38638965 PMC: 11024620. DOI: 10.1016/j.heliyon.2024.e29514.

The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy.

Chaudhri A, Bu X, Wang Y, Gomez M, Torchia J, Hua P Front Immunol. 2023; 14:1237715.

PMID: 37771579 PMC: 10524267. DOI: 10.3389/fimmu.2023.1237715.

References

Liu Y, An S, Ward R, Yang Y, Guo X, Li W . G protein-coupled receptors as promising cancer targets. Cancer Lett. 2016; 376(2):226-39. DOI: 10.1016/j.canlet.2016.03.031. View

Atkins M, Larkin J . Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. J Natl Cancer Inst. 2016; 108(6):djv414. DOI: 10.1093/jnci/djv414. View

Gong X, Azhdarinia A, Ghosh S, Xiong W, An Z, Liu Q . LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence. Mol Cancer Ther. 2016; 15(7):1580-90. DOI: 10.1158/1535-7163.MCT-16-0114. View

Zhou H, Telonis A, Jing Y, Xia N, Biederman L, Jimbo M . GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR. Cell Death Dis. 2016; 7:e2294. PMC: 4973341. DOI: 10.1038/cddis.2016.169. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Ten Hacken E, Burger J . Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacol Ther. 2014; 144(3):338-48. DOI: 10.1016/j.pharmthera.2014.07.003. View

Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View

Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C . Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012; 14(3):276-86. PMC: 3290742. DOI: 10.1038/ncb2432. View

Zhou H, Rigoutsos I . The emerging roles of GPRC5A in diseases. Oncoscience. 2015; 1(12):765-76. PMC: 4303886. DOI: 10.18632/oncoscience.104. View

10.

Kapushesky M, Emam I, Holloway E, Kurnosov P, Zorin A, Malone J . Gene expression atlas at the European bioinformatics institute. Nucleic Acids Res. 2009; 38(Database issue):D690-8. PMC: 2808905. DOI: 10.1093/nar/gkp936. View

11.

Hirano M, Zang L, Oka T, Ito Y, Shimada Y, Nishimura Y . Novel reciprocal regulation of cAMP signaling and apoptosis by orphan G-protein-coupled receptor GPRC5A gene expression. Biochem Biophys Res Commun. 2006; 351(1):185-91. DOI: 10.1016/j.bbrc.2006.10.016. View

12.

Wiley S, Sriram K, Liang W, Chang S, French R, McCann T . GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J. 2017; 32(3):1170-1183. PMC: 5892729. DOI: 10.1096/fj.201700834R. View

13.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

14.

Insel P, Zhang L, Murray F, Yokouchi H, Zambon A . Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf). 2011; 204(2):277-87. PMC: 3125423. DOI: 10.1111/j.1748-1716.2011.02273.x. View

15.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

16.

Insel P, Wilderman A, Zambon A, Snead A, Murray F, Aroonsakool N . G Protein-Coupled Receptor (GPCR) Expression in Native Cells: "Novel" endoGPCRs as Physiologic Regulators and Therapeutic Targets. Mol Pharmacol. 2015; 88(1):181-7. PMC: 4468643. DOI: 10.1124/mol.115.098129. View

17.

Zhang Y, Chen K, Sloan S, Bennett M, Scholze A, OKeeffe S . An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014; 34(36):11929-47. PMC: 4152602. DOI: 10.1523/JNEUROSCI.1860-14.2014. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Lappano R, Maggiolini M . G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011; 10(1):47-60. DOI: 10.1038/nrd3320. View

20.

van Jaarsveld M, Houthuijzen J, Voest E . Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer. Oncogene. 2015; 35(31):4021-35. DOI: 10.1038/onc.2015.467. View